Navigation Links
Nucleix Presents DNA Authentication Technology at 20th International Symposium on Human Identification
Date:10/14/2009

LAS VEGAS, Oct. 14 /PRNewswire/ -- Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers today presented its DNA authentication technology, a novel assay to distinguish between in-vivo (real) and in-vitro (fake) DNA, at the 20th International Symposium on Human Identification in Las Vegas, Nevada.

Earlier this year, Nucleix scientific co-founders Adam Wasserstrom, Ph.D., and Dan Frumkin, Ph.D., demonstrated that DNA evidence found at crime scenes can easily be falsified using basic equipment, know-how and access to DNA or a DNA database (1). Recognizing the need to safeguard the accuracy and credibility of DNA evidence in the field of forensics, the scientists developed a novel "DNA authentication" assay for combating this form of biological identity theft. Their study was published in the forensic industry's leading peer-reviewed scientific journal, "Forensic Science International: Genetics."

The Nucleix authentication assay is based on the fact that real DNA differs from fake DNA in biochemical properties, such as the methylation pattern. Specifically, in vivo-generated DNA contains genomic loci that are completely and consistently methylated and other loci that are unmethylated, differing from in vitro-synthesized DNA, which is completely unmethylated. Nucleix's novel proprietary assay can identify and differentiate between real and all potential types of fake DNA through methylation analysis of a set of genomic loci. In this symposium, Dr. Frumkin presented further developments of the company's DNA authentication technology. The Nucleix assay is comprised of a biochemical procedure followed by automatic signal analysis by a software application specifically designed for DNA authentication.

Details unveiled by Nucleix today demonstrate the ability to seamlessly integrate the company's DNA authentication technology with the current standard DNA profiling procedure, thus maintaining the integrity of DNA evidence without a significant increase in expensive resources such as labor and materials. The company's DNA authentication assay requires a minimal amount of DNA, makes use of equipment that is present in every forensic laboratory, and can be performed with profiling, thereby maintaining the current timeframe for sample analysis. In addition, profiling and authentication data can be combined into a single file, which is then analyzed by Nucleix's software, further reducing the complexity of integrating DNA profiling and authentication.

"We are pleased to have the opportunity to present our breakthrough DNA authentication technology to peers in the forensics field," said Drs. Wasserstrom and Frumkin. "Our goal is to provide an innovative Nucleix solution for ensuring DNA authentication that would enable rapid integration into current forensic analysis technology and workflow. This integration is necessary in order to maintain the high credibility of DNA evidence in the judiciary system."

About Nucleix

Nucleix, an emerging life science company specializing in forensic DNA analysis, has developed a "DNA authentication" assay for forensic casework samples with potential applications across multiple DNA analysis and validation fields. DNA fingerprinting has been established as one of the most important forensic tools in criminal investigations. Nucleix scientists have demonstrated the viability of creating artificial DNA and "biological identify theft."(1) Using basic equipment and know-how, DNA with any desired profile can be fabricated in the lab, and this artificial DNA can then be planted in crime scenes as fake evidence. Until recently, there has been no way to distinguish between genetic profiles obtained from falsified DNA samples, which can appear identical to real biological profiles based on current analytical protocols and technologies. Nucleix's proprietary assays can distinguish between "fake" (in-vitro synthesized) DNA, and "real" (in-vivo generated) DNA. The company is committed to developing state-of-the-art "DNA authentication" assays that can be integrated into the standard forensic procedure, in order to maintain the high credibility of DNA evidence in the courtroom and other uses. For additional information on Nucleix, please visit the company's website at http://www.nucleix.com.

(1) D. Frumkin, et al., Authentication of forensic DNA samples, Forensic Sci. Int. Genet. (2009), doi:10.1016/j.fsigen.2009.06.009

SOURCE Nucleix, Ltd.


'/>"/>
SOURCE Nucleix, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. InVitria Presents Zap-CHO Performance Results at PEACe Conference
2. The BBVA Foundation presents its Frontiers of Knowledge Awards
3. Versartis presents positive preclinical data on 2 product candidates at ENDO 09
4. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
5. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
6. GSA special paper presents new studies of Western US earth motion
7. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
8. AIUM presents 2009 Memorial Hall of Fame awards
9. AIUM presents 2009 Distinguished Sonographer award
10. AIUM presents 2009 William J. Fry Memorial Lecture award
11. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... 28, 2017 Summary This report ... Biochem and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/28/2017)... March 28, 2017  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member. ... Affairs ( North America ), will serve ... "We,re pleased to have Ipsen and Dr. ... Dan Leonard . "We welcome their insights in helping ...
(Date:3/28/2017)... -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or ... to treat cancers and other life-threatening conditions of the ... McGorry, CEO of Biostage, will present on the ... MassBio 2017 Annual Meeting on Thursday, March ... The 3D Printing and BioEngineering panel will ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
Breaking Biology Technology: